<SEC-DOCUMENT>0001193125-20-311156.txt : 20201207
<SEC-HEADER>0001193125-20-311156.hdr.sgml : 20201207
<ACCEPTANCE-DATETIME>20201207072430
ACCESSION NUMBER:		0001193125-20-311156
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20201207
DATE AS OF CHANGE:		20201207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-231098
		FILM NUMBER:		201371335

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d90736d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not complete and may be
changed. A registration statement relating to the shares has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell the shares and it
is not soliciting an offer to buy the shares in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-231098<BR> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED DECEMBER&nbsp;7, 2020 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Prospectus Supplement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(to Prospectus dated
April&nbsp;29, 2019) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>1,500,000 shares </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90736g68g84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>REPLIGEN CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering 1,500,000
shares of our common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;RGEN.&#148; The last
reported sale price of our common stock on the Nasdaq Global Select Market on December&nbsp;4, 2020 was $188.33 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Repligen Corporation, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#supcov90736_1">Risk Factors</A>&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-8</FONT> of this prospectus supplement, in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2019 and in our subsequent Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated herein by reference. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up to
225,000 additional shares from us at the public offering price, less underwriting discounts and commissions, within 30 days of the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission (the &#147;SEC&#148;) nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares of our common stock as set forth under &#147;Underwriting.&#148; Delivery of the shares of common stock will be made
on or about December &nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint
Book-Running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Stifel</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Co-Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Craig-Hallum&nbsp;Capital&nbsp;Group</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Stephens&nbsp;Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_8">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_11">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_13">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_14">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_15">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_16">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_17">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_18">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_19">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_20">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_21">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_22">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_23">FORMS OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_24">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_25">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_26">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom90736_27">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is part of the registration statement that we filed with the SEC using a &#147;shelf&#148; registration process and consists of two parts. The
first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference, gives
more general information, some of which may not apply to this offering. Generally, when we refer to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement and any free writing prospectus we authorize for use
in connection with this offering may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If information in this prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by reference that was filed
with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. This prospectus supplement, the accompanying prospectus, the documents incorporated by reference into each of them and any free writing
prospectus we authorize for use in connection with this offering include important information about us, the common stock and other information should you consider before investing in the common stock. See &#147;Incorporation of Certain Information
by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any
document that is incorporated by reference herein or in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements,
and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties and covenants were made as of a date prior to the date of this prospectus supplement, and facts and circumstances may have
changed since such date. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We take no responsibility for, and can provide no assurances as to the reliability of, any information that is in addition to or different from that contained
or incorporated by reference in this prospectus supplement and the accompanying prospectus. We are not offering to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information
contained or incorporated by reference in this prospectus supplement or the accompanying prospectus is accurate as of any date other than as of the date of this prospectus supplement or the accompanying prospectus, as the case may be, or in the case
of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition, liquidity,
results of operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references in this prospectus supplement or the accompanying prospectus to
&#147;Repligen,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; mean Repligen Corporation and our subsidiaries, unless we state otherwise or the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference contain references to trademarks,
service marks and trade names owned by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this prospectus supplement, the accompanying prospectus and the information incorporated herein and
therein, including logos, artwork, and other visual displays, may appear without the&reg; or <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references are not intended to indicate, in any way, that we will not assert,
to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies&#146; trade names, service marks or trademarks
to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement, the accompanying prospectus or any
related free writing prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain, and any free writing
prospects we authorize for use in connection with this offering may contain, statements that are not historical facts and are considered forward-looking within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the
Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements may contain projections of our future results of operations or of our financial position or state other
forward-looking information. In some cases you can identify these statements by forward-looking words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;continue,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; &#147;plan,&#148; &#147;projected&#148; or the negative of such words or other similar words or phrases. We believe that it is important to communicate our
future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors are cautioned not to unduly rely on forward-looking statements because they involve known and unknown risks,
uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these
forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model and strategic plans for our business, products and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ultimate impact of the coronavirus pandemic on our business or financial results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of current and future collaborative or supply relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully grow our bioprocessing business, including as a result of acquisitions,
commercialization or partnership opportunities, and our ability to develop new products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the growth of our business into new markets and geographies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish key customer relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish key supplier relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our expenses, future revenues and capital requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully integrate our recently acquired businesses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations relating to the synergies, cost savings and other benefits of our recent acquisitions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to competitors in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected or intended use of proceeds from this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors&#148; below and in any
documents incorporated by reference herein. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given these uncertainties, readers should not place undue reliance on our forward-looking
statements. These forward-looking statements speak only as of the date on which the statements were made and are not guarantees of future performance. Except as may be required by applicable law, we do not undertake or intend to update any
forward-looking statements after the date of this prospectus supplement or the accompanying prospectus or the respective dates of documents incorporated by reference herein or therein that include forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying
prospectus. This summary may not contain all the information that you should consider before making your investment decision. You should read this entire prospectus supplement and the accompanying prospectus carefully, especially the risks of
investing in our securities discussed under &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-8</FONT> of this prospectus supplement, along with our consolidated financial statements and notes to those consolidated
financial statements and the other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus we authorize for use in connection with this offering, before making
an investment decision. This prospectus supplement may add to, update or change information in the accompanying prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen and its subsidiaries, collectively doing business as Repligen Corporation, is a global life sciences company that develops and commercializes
highly innovated bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
the overall market for biologics continues to grow and expand, our customers &#150; primarily large biopharmaceutical companies and contract development and manufacturing organizations &#150; face critical production cost, capacity, quality and time
pressures. Built to address these concerns, our products are helping to set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic
drugs &#150; including monoclonal antibodies, or mAb, recombinant proteins, vaccines and gene therapies &#150; that are improving human health worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biological drug
manufacturing. Building on over 35 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our passion for innovation and the customer-first culture that drives our entire organization. We continue to
capitalize on opportunities to maximize the value of our product platform through both organic growth initiatives (internal innovation and commercial leverage) and targeted acquisitions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Products </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our bioprocessing business is comprised of
four main franchises, three of which we sell directly <FONT STYLE="white-space:nowrap">to&nbsp;end-users&nbsp;(Chromatography,</FONT> Filtration and Process Analytics) and one that we sell primarily through supply agreements (Proteins). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of our revenue comes from consumable and/or single-campaign, or <FONT STYLE="white-space:nowrap">single-use,</FONT> products as compared to
associated equipment. The customization, scalability and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plug-and-play</FONT></FONT> convenience of consumable and/or <FONT STYLE="white-space:nowrap">single-use</FONT> products, and
in many cases the closed nature of our technologies, make them ideal for use in biologics manufacturing processes where contamination risk is a critical concern of our customers. Based on internal estimates and assumptions, we believe our Proteins,
Filtration, Chromatography and Process Analytics franchises sell into addressable markets of approximately $550&nbsp;million, $1.7&nbsp;billion, $425&nbsp;million and $500&nbsp;million, respectively, for an aggregate addressable market of
approximately $3.2&nbsp;billion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chromatography </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs.
The main driver of growth in this portfolio is our OPUS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <FONT STYLE="white-space:nowrap">pre-packed</FONT> column product line. Additional chromatography products include our affinity capture
resins, such as CaptivA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Protein A resins, that are used in a small number of commercial drug processes and our ELISA test kits, used by quality control departments to detect and measure the
presence of leached Protein A and/or growth factor in the final product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Filtration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Filtration products offer a number of advantages to manufacturers of biologic drugs and are used in development, clinical and commercial-scale production.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Filtration portfolio is our largest and most diverse in terms of product type and the span of workflow unit operations addressed. The continued
expansion of our Filtration offering supports our strategy of bringing fully integrated systems to our customers, and better connecting upstream to downstream unit operations. Components of this portfolio include hollow fiber as well as flat sheet
filters, single-use devices that incorporate these filters, <FONT STYLE="white-space:nowrap">single-use</FONT> flow paths with custom components and assemblies, as well as skids, software and carboys for systems integration. We have several
&#147;firsts&#148; to market in our portfolio including our Alternating Tangential Flow (ATF), and Tangential Flow Depth Filtration (TFDF) solutions for perfusion and process intensification, and for more efficient harvest clarification,
respectively. Across our Filtration portfolio, our products can be used in a variety of unit operations for mAb, gene therapy and vaccine production; cell culture seed train and production, transfection, clarification, formulation and concentration
included. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Process Analytics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Process
Analytics products complement and support our Filtration, Chromatography and Proteins franchises as they <FONT STYLE="white-space:nowrap">allow&nbsp;end-users</FONT> to <FONT STYLE="white-space:nowrap">make&nbsp;at-line</FONT> or <FONT
STYLE="white-space:nowrap">in-line</FONT> absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our SoloVPE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Slope Spectroscopy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> system is
used for offline and <FONT STYLE="white-space:nowrap">at-line</FONT> absorbance measurements for protein concentration determination in process development, manufacturing and quality control settings. Our FlowVPE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Slope Spectroscopy provides <FONT STYLE="white-space:nowrap">in-line</FONT> protein concentration measurement for filtration, chromatography and fill-finish applications. A key benefit of this <FONT
STYLE="white-space:nowrap">in-line</FONT> solution is the ability to monitor a manufacturing process in real time. We are developing a next-generation FlowVPE to incorporate <FONT STYLE="white-space:nowrap">GMP-compliant</FONT> software for
production-scale biologics manufacturing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proteins </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Proteins products are represented by our Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream
purification of mAbs. We also sell cell culture growth factor products, which are a key component of cell culture media used in upstream bioprocessing to increase cell density and improve product yield. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ARTeSYN Biosolutions
Acquisition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;27, 2020, we entered into an Equity and Asset Purchase Agreement with ARTeSYN Biosolutions Holdings Ireland Limited, a
company organized under the laws of Ireland, or ARTeSYN, Third Creek Holdings, LLC, a Nevada limited liability company, or Third Creek, Alphinity, LLC, a Nevada limited liability company, or Alphinity, and together with Third Creek, the Sellers, and
Michael Gagne, solely in his capacity as the representative of the Sellers, pursuant to which we acquired (i)&nbsp;all of the outstanding equity securities of ARTeSYN and (ii)&nbsp;certain assets from Alphinity related to the business of ARTeSYN,
collectively, the ARTeSYN Acquisition, for approximately $200&nbsp;million, comprised of approximately $130&nbsp;million in cash to Third Creek and Alphinity and approximately $70&nbsp;million in our common stock to Third Creek. The transaction
closed on December&nbsp;3, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARTeSYN, headquartered in Waterford, Ireland, is a biosystems innovator that is focused on <FONT
STYLE="white-space:nowrap">single-use</FONT> chromatography and filtration systems, with high degree of automation and low <FONT STYLE="white-space:nowrap">hold-up</FONT> volumes, which are important features and benefits in bioprocessing. The
ARTeSYN acquisition, combined with the recent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisitions of Engineered Molding Technology LLC, or EMT, and <FONT STYLE="white-space:nowrap">Non-Metallic</FONT> Systems, or NMS, further establishes Repligen in the market for <FONT
STYLE="white-space:nowrap">single-use</FONT> systems and associated integrated flow path assemblies or fluid management. ARTeSYN offers a suite of <FONT STYLE="white-space:nowrap">single-use</FONT> systems for chromatography, filtration, and
media/buffer prep workflows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Metallic</FONT> Solutions Acquisition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2020, we entered into a Stock Purchase Agreement with NMS, a Massachusetts corporation, and William Mallone&eacute; and Derek Masser, the
legal and beneficial owners of NMS, to purchase NMS, which transaction subsequently closed on October&nbsp;20, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NMS, which is headquartered in
Auburn, Massachusetts, is a manufacturer of fabricated plastics, custom containers, and related assemblies and components used in the manufacturing of biologic drugs. NMS&#146;s products will complement and expand Repligen&#146;s <FONT
STYLE="white-space:nowrap">single-use</FONT> product offerings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in May 1981 under the laws of the State of Delaware. Our mailing address and executive offices are located at 41 Seyon Street, Waltham, MA
02453 and our telephone number at that address is (781) <FONT STYLE="white-space:nowrap">250-0111.</FONT> We maintain an Internet website at the following address: www.repligen.com. The information on, or that can be accessed through, our website
does not constitute part of this prospectus supplement, and the reference to our website address is included in this prospectus supplement as an inactive textual reference only. You should not rely on any such information in making the decision
whether to invest in our common stock. Our common stock trades on the Nasdaq Global Select Market under the symbol &#147;RGEN.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Common Stock Offered by Us</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1,500,000 shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Option to Purchase Additional Shares of Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">We have granted the underwriters an option exercisable for 30 days after the date of this prospectus supplement to purchase up to 225,000 additional shares from us.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Common Stock to be Outstanding Immediately after This Offering</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">54,106,700 shares (or 54,331,700 shares if the underwriters exercise in full their option to purchase additional shares).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Use of Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us, will be approximately $269.4&nbsp;million (or approximately $309.8&nbsp;million if the underwriters exercise their option to purchase additional shares of common stock in full), based on an assumed public offering price of
$188.33 per share (the last reported sale price of our common stock on the Nasdaq Global Select Market on December&nbsp;4, 2020).</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for working capital and other general corporate purposes. Net proceeds from this offering may also be used
to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. We have not entered into any agreements or commitments with respect to any acquisitions or investments at this time. See &#147;Use of
Proceeds.&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Risk Factors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-8</FONT> of this prospectus supplement, in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, and in our subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated by reference herein, for a discussion of factors
that you should read and consider before investing in our securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Nasdaq Global Select Market Symbol</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>&#147;RGEN&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering as shown above is based on
52,606,700 shares outstanding as of September&nbsp;30, 2020. This number of shares excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">372,990 shares of our common stock issued on December&nbsp;3, 2020 in connection with the ARTeYSN Acquisition;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">723,914 shares of our common stock issuable upon the exercise of stock options outstanding under the Second
Amended and Restated 2001 Repligen Corporation Stock Plan, or the 2001 Plan, the Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan, or the 2012 Plan, and the Repligen Corporation 2018 Stock Option and Incentive Plan, or
the 2018 Plan, and collectively with the 2001 Plan and the 2012 Plan, the Plans, at a weighted average exercise price of $41.03 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">675,567 shares of our common stock issuable upon the vesting of outstanding restricted stock units issued under
the Plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,325,314 shares of our common stock reserved for future issuance under the 2018 Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any shares of our common stock issuable upon the conversion of the 0.375% Convertible Senior Notes due 2024, or
the Senior Notes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any of these options are exercised, restricted stock units vest, new options are issued
under our equity incentive plans and subsequently exercised, we issue additional shares of common stock in the future, or the Senior Notes convert to, or are exchanged for, common stock, there will be further dilution to the investors participating
in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus supplement assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the underwriters do not exercise their option to purchase up to 225,000 additional shares of our common
stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no options, restricted stock units, warrants, or shares of common stock were issued or converted after
September&nbsp;30, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supcov90736_1"></A><A NAME="suprom90736_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. In addition to the other information contained in this prospectus supplement, the
accompanying prospectus, the documents incorporated by reference herein and therein and any free writing prospectus we authorize for use in connection with this offering, you should carefully consider the risks discussed below and under the heading
&#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, filed with the SEC on February&nbsp;26, 2020, and in our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2020, June&nbsp;30, 2020 and September&nbsp;30, 2020, as filed with the SEC on May&nbsp;6, 2020, July&nbsp;30, 2020 and November&nbsp;5, 2020, respectively, before making a
decision about investing in our securities. These risks and uncertainties may not be the only ones we face. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If any of
these risks occur, our business, financial condition and operating results could be harmed, the trading price of our common stock could decline and you could lose part or all of your investment. The risks discussed below also include forward-looking
statements and our actual results may differ substantially from those discussed in these forward-looking statements. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risks Related to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to
execute our business strategy is subject to a number of risks of which you should be aware before you decide to invest in our common stock. In particular, you should consider the following risks, which are discussed more fully in our Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 and in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2020, June&nbsp;30, 2020 and
September&nbsp;30, 2020, which are incorporated herein by reference: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product revenue may be negatively impacted by a number of factors, including without limitation, competition
in the bioprocessing market, our historical reliance on a limited number of large customers, our ability to develop or acquire additional bioprocessing products in the future, our ability to manufacture our bioprocessing products sufficiently and
timely, and our ability to effectively penetrate the bioprocessing products market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on a limited number of suppliers or, for certain of our products, one supplier, and we may not be able to
find replacements or immediately transition to alternative suppliers, which could have a material adverse effect on our financial condition, results of operations and reputation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to achieve sufficient market acceptance for our bioprocessing products, and our results of
operations and competitive position could suffer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our products do not perform as expected or the reliability of the technology on which our products are based
is questioned, we could experience lost revenue, delayed or reduced market acceptance, increased cost and damage to our reputation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to manufacture our products in sufficient quantities and in a timely manner, our operating
results will be harmed, our ability to generate revenue could be diminished and our gross margin may be negatively impacted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acquisitions we have completed, including our recent acquisitions of ARTeSYN, NMS or EMT, or may in the future
complete, may expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our results of operations could be negatively affected by potential fluctuations in foreign currency exchange
rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to hire and retain skilled personnel, including technical, sales and marketing personnel, then
we will have trouble developing and marketing our products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain, maintain and protect our intellectual property rights related to our products, we may
not be able to compete effectively or succeed commercially. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock historically has been volatile, which may affect the price at which you could sell any shares of our common stock.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price for our common stock historically has been highly volatile and could continue to be subject to wide fluctuations. The market
price for our common stock has varied between a high price of $212.55 on November&nbsp;12, 2020 and a low price of $78.41 on March&nbsp;23, 2020 in the twelve-month period ending on December&nbsp;4, 2020. This volatility may affect the price at
which you could sell the shares of our common stock, and the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Our stock price is likely to continue to be volatile and subject to significant price
and volume fluctuations in response to market and other factors, including: variations in our quarterly operating results from our expectations or those of securities analysts or investors; downward revisions in securities analysts&#146; estimates;
and announcement by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; and the other factors discussed herein, in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
for the year ended December&nbsp;31, 2019, in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2020, June&nbsp;30, 2020 and September&nbsp;30, 2020 or in future periodic reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering as well as our existing cash and we may not use them effectively.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described
in the section entitled &#147;Use of Proceeds,&#148; as well as our existing cash, and you will be relying on the judgment of our management regarding such application. You will not have the opportunity, as part of your investment decision, to
assess whether the proceeds from this offering and our existing cash are being used effectively. Our management might not apply the net proceeds or our existing cash in ways that ultimately increase the value of your investment. If we do not invest
or apply the net proceeds from this offering or our existing cash in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. Pending their use, we may invest the net
proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any future sales of our common stock or equity-linked securities in the public market or the perception that these sales might occur, including as a
result of the issuance of any additional equity-linked securities or the conversion of any of our existing equity-linked securities, including the Senior Notes, could lower the market price for our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any future sales of our common stock or equity-linked securities in the public market or the perception that these sales might occur, including as a result of
the issuance of any additional equity-linked securities or the conversion of any of our existing equity-linked securities, including the Senior Notes, could lower the market price for our common stock and could impair our ability to raise capital
through the sale of additional equity or equity-linked securities. In addition, a substantial number of shares of our common stock is reserved for issuance upon the exercise of stock options, the vesting of restricted stock units and upon conversion
of the Senior Notes. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the sale of
substantial amounts of our common stock could adversely impact its price. As of September&nbsp;30, 2020, we had outstanding 52,606,700 shares of our common stock, options to purchase 723,914 shares of our common stock (of which 339,191 were
exercisable as of that date) and restricted stock units to acquire 675,567 shares of our common stock. Furthermore, we issued 372,990 shares of our common stock to Third Creek on December&nbsp;3, 2020 in connection with the ARTeSYN acquisition. As
early as the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the consummation of the ARTeSYN acquisition, the shares of stock issued to Third Creek as consideration may become eligible for sale in the public market. The sale or the
availability for sale of a large number of shares of our common stock in the public market could cause the price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our directors and executive officers have agreed that for a period of 60 days after the date of this
prospectus supplement, subject to specified exceptions, we or they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of our common stock or securities convertible into or exchangeable or
exercisable for any shares of our common stock. Sales of common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock by us, our directors or executive officers after the expiration of the lockup
period could have a material adverse effect on the trading price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by
us, will be approximately $269.4&nbsp;million (or approximately $309.8&nbsp;million if the underwriters exercise their option to purchase additional shares of common stock in full), based on an assumed public offering price of $188.33 per share (the
last reported sale price of our common stock on the Nasdaq Global Select Market on December&nbsp;4, 2020). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed
public offering price of $188.33 per share (the last reported sale price of our common stock on the Nasdaq Global Select Market on December&nbsp;4, 2020), would increase (decrease) the net proceeds to us from this offering by approximately
$1.4&nbsp;million ($1.4 million), assuming the number of shares of common stock offered by us, as set forth on the cover page of this prospectus supplement, remains the same, and after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for working capital and other general corporate purposes. Net
proceeds from this offering may also be used to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. We have not entered into any agreements or commitments with respect to any acquisitions
or investments at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and
business condition. As of the date of this prospectus supplement, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the
uses set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the use of the net proceeds from this offering, we intend to invest the net proceeds in short-term, interest-bearing,
investment-grade securities, certificates of deposit or government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not paid any dividends since our inception and do not intend to pay any dividends on our common stock in the foreseeable future. We anticipate that we
will retain all earnings, if any, to support our operations. Any future determination as to the payment of dividends will be at the sole discretion of our Board of Directors and will depend on our financial condition, results of operations, capital
requirements, contractual obligations and other factors our Board of Directors deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_8"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering the shares of common stock described in this prospectus supplement through a number of underwriters. J.P. Morgan Securities LLC and Stifel,
Nicolaus&nbsp;&amp; Company, Incorporated are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions
of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this
prospectus supplement, the number of shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig-Hallum Capital Group LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephens Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair &amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are committed to purchase all of the common shares offered by us if they purchase any shares. The
underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the common shares directly to the public at the public offering price set forth on the cover page of this prospectus
supplement and to certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share from the public offering price. After the offering of the shares to the public, the offering price and other selling terms may be changed by the underwriters. Sales of shares made outside
of the United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have an option to buy up to 225,000 additional shares of common
stock from us. The underwriters have 30 days from the date of this prospectus supplement to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will
purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being
offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of
common stock. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and
full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;option</B><br><B>to<BR>purchase<BR>additional<BR>shares&nbsp;exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;full&nbsp;option<BR>to<BR>purchase<BR>additional<BR>shares exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal
and accounting expenses, but excluding the underwriting discounts and commissions, will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately $425,000. We have agreed to reimburse the underwriters in an amount of up to $10,000 for expenses relating to the compliance of this offering with the rules of the Financial
Industry Regulatory Authority, Inc., or FINRA. In accordance with FINRA Rule 5110, this reimbursed FINRA fee is deemed underwriting compensation for this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any,
participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed that we will not,
without the prior written consent of J.P. Morgan Securities LLC, for a period of 60 days after the date of this prospectus supplement (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any common stock or any securities convertible into or exercisable or exchangeable for common stock, (ii)&nbsp;enter
into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of common stock, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of common stock
or such other securities, in cash or otherwise, (iii)&nbsp;file any registration statement under the Securities Act in respect of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or
(iv)&nbsp;publicly announce the intention to do any of the foregoing; provided that we may (1)&nbsp;effect the transactions contemplated by the underwriting agreement, (2)&nbsp;issue common stock or options to purchase common stock, or issue common
stock upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement, (3)&nbsp;permit or allow the vesting of or removal or lapse of restrictions on restricted stock or other awards under existing employee
benefits plans or agreements in accordance with the terms of such plans or agreements, (4)&nbsp;issue options, restricted stock units or other awards to newly hired employees, (5)&nbsp;file any registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto in respect of securities offered pursuant to the terms of existing employee benefits, (6)&nbsp;issue common stock upon the exchange, conversion or redemption of any Senior Notes and
(7)&nbsp;issue common stock to one or more counterparties in connection with the consummation of any merger, asset acquisition or other business combination transaction, or any strategic partnership, joint venture, collaboration or license of any
business, products, technology in an amount that does not exceed 10% of the total outstanding common stock immediately following the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors and executive officers have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the
commencement of this offering pursuant to which each of these persons, for a period of 60 days after the date of this prospectus supplement, may not, without the prior written consent of J.P. Morgan Securities LLC, offer, sell, contract to sell
(including any short sale), pledge, hypothecate, establish an open &#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act, grant any option, right or warrant for the
sale of, purchase any option or contract to sell, sell any option or contract to purchase, or otherwise encumber, dispose of or transfer, or grant any rights with respect to, directly or indirectly, any shares of common stock or securities
convertible into or exchangeable or exercisable for any shares of common stock, enter into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic
consequences of ownership of the common stock, whether any such aforementioned transaction is to be settled by delivery of the common stock or such other securities, in cash or otherwise, or publicly disclose the intention to make any such offer,
sale, pledge or disposition, or to enter into any such transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of J.P. Morgan Securities LLC, which consent may be withheld in J.P. Morgan Securities LLC&#146;s
sole discretion. Such restrictions will not, subject to certain limitations and exceptions, apply to: (i)&nbsp;the receipt, exercise, cashless or net exercise, vesting or forfeiture of, or removal or lapse of restrictions on, any stock option,
common stock issued upon exercise of a stock option, restricted stock, restricted stock unit or other awards pursuant to any existing employee benefit plan or agreement, (ii)&nbsp;transactions relating to common stock acquired in open market
transactions after this offering, (iii)&nbsp;the transfer or sale of common stock, or securities convertible into or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchangeable or exercisable for any shares of common stock, by operation of law, such as pursuant to a domestic relations order or in connection with a divorce settlement, (iv)&nbsp;forfeitures
of common stock to the Company during the 60 day <FONT STYLE="white-space:nowrap">lock-up</FONT> period only to satisfy tax withholding requirements, (v)&nbsp;the entry into any trading plan established pursuant to Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that such plan does not provide for any sales or other dispositions of common stock or securities convertible into or exchangeable or exercisable for any shares of common
stock during the 60 day <FONT STYLE="white-space:nowrap">lock-up</FONT> period, (vi)&nbsp;transfers as a bona fide gift to a charity or educational institution or, in some cases, to a charitable trust, provided such transfers are not for value,
(vii)&nbsp;transfers or distributions pursuant to any bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the Company&#146;s capital stock involving a change of control of the Company, or
(viii)&nbsp;certain transfers or sales of common stock, or securities convertible into or exchangeable or exercisable for any shares of common stock, pursuant to a trading plan established pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act that has been entered into prior to the date of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and has been disclosed to J.P. Morgan Securities LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;RGEN.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of
common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common stock, which
involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales
may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that
amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will
consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely
to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a
naked short position, they will purchase shares in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, pursuant to Regulation M
of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters
purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price
of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters
may carry out these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this
prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering
material or advertisements in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations
of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus
supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain
commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition,
from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity
securities or loans, and may do so in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area and the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area and the United Kingdom (each a &#147;Relevant State&#148;), no shares have been offered or will
be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in
another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following
exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the underwriters; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the
underwriters and the Company that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus
Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on
behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so
defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of
this provision, the expression an &#147;offer to the public&#148; in relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as
to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus
Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to
whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not
result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person in the
United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may
be made or taken exclusively by relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock must be made in accordance with an exemption from, or in a transaction not subject to,
the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting
Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in
connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters relating to the shares of common stock offered hereby will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts.
Covington&nbsp;
&amp; Burling LLP, New York, New York, is counsel to the underwriters in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_10"></A>EXPERTS
 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Repligen Corporation appearing in Repligen Corporation&#146;s Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2019, and the effectiveness of Repligen Corporation&#146;s internal control over financial reporting as of December&nbsp;31, 2019 have been audited by Ernst&nbsp;&amp;
Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon
such reports given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_11"></A>WHERE YOU CAN FIND
ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities
Act with respect to the shares of common stock offered by this prospectus supplement. This prospectus supplement does not contain all the information set forth in the registration statement and its exhibits and schedules, portions of which have been
omitted as permitted by the rules and regulations of the SEC. You should read the registration statement and its exhibits and schedules carefully for provisions that may be important to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov that contains
periodic and current reports, proxy and information statements, and other information regarding registrants that are filed electronically with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These documents are also available, free of charge, through the &#147;Investors&#148; section of our website, which is located at www.repligen.com.
Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus and you should not consider information on our website to be part of this prospectus supplement or the accompanying
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom90736_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by
referring you to these documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file after the date hereof with the SEC will automatically update and supersede the information
already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
except as to any portion of any future report or document that is not deemed filed under such provisions, after the date of this prospectus supplement and prior to the termination of this offering: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520050136/d862842d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2019, as filed with the SEC on February&nbsp;26, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520134898/d915034d10q.htm">March&nbsp;31,
 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520204153/d939099d10q.htm">June&nbsp;
30, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520286931/d945763d10q.htm">September&nbsp;30, 2020</A>, as filed with the SEC on May&nbsp;6, 2020, July&nbsp;30, 2020 and
November&nbsp;5, 2020, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 from our <A HREF="http://www.sec.gov/Archives/edgar/data/730272/000119312520123263/d868307ddef14a.htm">definitive proxy statement</A> on Schedule 14A (other than
information furnished rather than filed), which was filed with the SEC on April&nbsp;28, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520051061/d891498d8k.htm">February&nbsp;27,
 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520143990/d812938d8k.htm">May&nbsp;
15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520168359/d944403d8k.htm">June&nbsp;
15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520182310/d947904d8k.htm">June&nbsp;
29, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520191159/d29647d8k.htm">July&nbsp;
10, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/730272/000119312520278422/d66585d8k.htm">October&nbsp;27, 2020</A> (in each case, other than information furnished rather than filed); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration statement on Form <FONT
STYLE="white-space:nowrap">8-A,</FONT> which was filed with the SEC in paper format on May&nbsp;27, 1986, including any amendment or report filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus supplement, at no
cost by writing or telephoning us at the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Repligen Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 Seyon Street, Bldg. 1, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Waltham, MA, 02453 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Secretary, (781) <FONT STYLE="white-space:nowrap">250-0111</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website at
<I>www.sec.gov</I> or on our website at <I>www.repligen.com</I>. The information contained on, or that can be accessed through, our website does not constitute part of this prospectus supplement, and the reference to our website address is included
in this prospectus supplement as an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>REPLIGEN CORPORATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90736g54m58.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By this prospectus, we may offer and sell from time to time, in one or more offerings, common stock, preferred stock, debt securities, warrants or any
combination thereof as described in this prospectus. The warrants may be convertible into or exercisable or exchangeable for common stock or preferred stock, the preferred stock may be convertible into or exchangeable for common stock and the debt
securities may be convertible into or exchangeable for common stock or preferred stock. You should carefully read this prospectus, any prospectus supplement and any related free writing prospectus, as well as any documents incorporated in any of the
foregoing by reference, before you invest in our securities. This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. The prospectus supplement or any related free writing prospectus may also add to,
update, supplement or clarify information contained in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Select Market under the symbol
&#147;RGEN.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell our securities to or through one or more agents, underwriters, dealers or other third parties or directly to one
or more purchasers on a continuous or delayed basis. If agents, underwriters or dealers are used to sell our securities, we will name them and describe their compensation in a prospectus supplement. The price to the public of our securities and the
net proceeds we expect to receive from the sale of such securities will also be set forth in a prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES
INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY REVIEW THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE HEADING &#147;<U><A HREF="#toc668819_5">RISK FACTORS</A></U>&#148; ON PAGE 5 OF THIS PROSPECTUS AS WELL AS THOSE CONTAINED IN THE APPLICABLE
PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS OR THE APPLICABLE PROSPECTUS SUPPLEMENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is April&nbsp;29, 2019. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_2">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_3">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_6">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_10">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_11">FORMS OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_12">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_13">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc668819_15">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are responsible for the information contained and incorporated by reference in this prospectus, in any accompanying
prospectus supplement, and in any related free writing prospectus we prepare or authorize. We have not authorized anyone to give you any other information, and we take no responsibility for any other information that others may give you. If you are
in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this documentation are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in
this document does not extend to you. The information contained in this document speaks only as of the date of this document, unless the information specifically indicates that another date applies. Our business, financial condition, results of
operations and prospectus may have changed since those dates. </B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_1"></A><A NAME="suprom90736_13"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC, as
a &#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration, we may offer shares of our common stock and preferred stock, various series of
warrants to purchase common stock or preferred stock, debt securities or any combination thereof, from time to time in one or more offerings. This prospectus only provides you with a general description of the securities we may offer. Each time we
offer our securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the specific terms of the offering. We may also authorize one or more free writing prospectuses to be provided to
you that may contain material information relating to these offerings. This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. Each such prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into this prospectus. We urge you to carefully read this prospectus, any applicable prospectus
supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the headings &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information
by Reference&#148; before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with information in addition to or
different from that contained or incorporated by reference into this prospectus, any applicable prospectus supplement and any related free writing prospectus. We take no responsibility for, and can provide no assurances as to the reliability of, any
information not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby, but only
under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front
of the document and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related
free writing prospectus, or any sale of a security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the
documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed,
will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find Additional
Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise mentioned or unless the context requires otherwise, throughout this prospectus, any applicable
prospectus supplement and any related free writing prospectus, the words &#147;Repligen,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the &#147;company&#148; or similar references refer to Repligen Corporation and its subsidiaries; and the
term &#147;securities&#148; refers collectively to our common stock, preferred stock, warrants to purchase common stock or preferred stock, debt securities, or any combination of the foregoing securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated herein by reference contain references to trademarks, service marks and trade names owned by
us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this prospectus and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or &#153; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable
licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies&#146; trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other
companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable<I> </I>prospectus supplement or any related free writing prospectus are the property of their respective owners. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_2"></A><A NAME="suprom90736_14"></A>WHERE YOU CAN FIND ADDITIONAL
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we have filed with the SEC. Certain information in the
registration statement has been omitted from this prospectus in accordance with the rules of the SEC. We are subject to the information requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and, in accordance
therewith, file annual, quarterly and special reports, proxy statements and other information with the SEC. These documents also may be accessed through the SEC&#146;s Electronic Data Gathering, Analysis and Retrieval system, or EDGAR, via
electronic means, including the SEC&#146;s home page on the Internet (<I>www.sec.gov</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the authority to designate and issue
more than one class or series of stock having various preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. See &#147;Description of
Securities.&#148; We will furnish a full statement of the relative rights and preferences of each class or series of our stock which has been so designated and any restrictions on the ownership or transfer of our stock to any stockholder upon
request and without charge. Written requests for such copies should be directed to Repligen Corporation, 41 Seyon Street, Bldg.1, Suite 100, Waltham, MA 02453, Attention: Secretary, or by telephone request to
<FONT STYLE="white-space:nowrap">(781)&nbsp;250-0111.</FONT> Our website is located at <I>http://www.repligen.com</I>. Information contained on our website is not incorporated by reference into this prospectus and, therefore, is not part of this
prospectus or any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_3"></A><A NAME="suprom90736_15"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that
we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file after the date hereof with the SEC will automatically
update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, except as to any portion of any future report or document that is not deemed filed under such provisions, after the date of this prospectus and prior to the termination of this offering: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/730272/000119312519060645/d682580d10k.htm">Form <FONT
STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2018, as filed with the SEC on March&nbsp;1, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/730272/000119312519060645/d682580d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2018 from our definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/730272/000119312519111021/d686074ddef14a.htm">Schedule 14A</A> (other
than information furnished rather than filed), which was filed with the SEC on April&nbsp;18, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on <A HREF="http://www.sec.gov/Archives/edgar/data/730272/000119312519120904/d737524d8k.htm">Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed</A> with the SEC on April&nbsp;26, 2019 (other than information furnished rather than filed) and <A HREF="http://www.sec.gov/Archives/edgar/data/730272/000119312519125167/d600172d8ka.htm">Form
8-K/A</A> filed with the SEC on April&nbsp;29, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration statement on Form <FONT
STYLE="white-space:nowrap">8-A,</FONT> which was filed with the SEC in paper format on May&nbsp;27, 1986, including any amendment or report filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at
no cost by writing or telephoning us at the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation, 41 Seyon Street, Bldg.1, Suite 100, Waltham, MA, 02453, Attention:
Secretary, <FONT STYLE="white-space:nowrap">(781)&nbsp;250-0111.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the
SEC&#146;s website at <I>www.sec.gov</I> or on our website at <I>www.repligen.com</I>. The information contained in, or that can be accessed through, our website is not part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You
should read the exhibits carefully for provisions that may be important to you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_4"></A><A NAME="suprom90736_16"></A>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts
and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148;
&#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;continue,&#148; and similar expressions, or the negative of these terms, or similar
expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by
reference to the factors discussed throughout this report, and in particular those factors referenced in the section &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the sections entitled &#147;About this Prospectus&#148; and &#147;Risk Factors,&#148; contains forward- looking
statements that are based on our management&#146;s belief and assumptions and on information currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks,
uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these
forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the acceptance by the market of our products, the implementation of our business model, strategic plans for our business, including potential
acquisitions of businesses or new products, products and technology, the scope of protection we are able to establish and maintain for intellectual property rights covering our products and technology, estimates of our expenses, future revenues and
capital requirements, our ability to maintain and establish key customer relationships, and our financial performance, developments relating to our competitors and our industry. Given these uncertainties, you should not place undue reliance on these
forward-looking statements. You should read this prospectus, any supplements to this prospectus and the documents that we incorporate by reference in this prospectus with the understanding that our actual future results may be materially different
from what we expect. Except as required by law, we do not undertake any obligation to update or revise any forward-looking statements contained in this prospectus or any supplement to this prospectus, whether as a result of new information, future
events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_5"></A><A NAME="suprom90736_17"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully consider the risks described in the documents incorporated by
reference in this prospectus and any prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our business,
financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you may lose
all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these
forward-looking statements as a result of certain factors, including the risks described in the documents incorporated herein by reference, including (i)&nbsp;our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> which
is on file with the SEC and is incorporated herein by reference and (ii)&nbsp;other documents we file with the SEC that are deemed incorporated by reference into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_6"></A><A NAME="suprom90736_18"></A>ABOUT THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading provider of advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. Our
products are made to substantially increase biopharmaceutical manufacturing efficiencies and flexibility. As the global biologics market continues to experience strong growth and expansion, our customers &#150; primarily large biopharmaceutical
companies and contract manufacturing organizations &#150; face critical production cost, capacity, quality and time pressures that our products are made to address. Our commitment to bioprocessing is helping to set new standards for the way our
customers manufacture biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines and gene therapies. We are dedicated to inspiring advances in bioprocessing as a trusted partner in the production of biologic drugs that improve
human health worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream
and downstream processes in biologic drug manufacturing. Building on over 35 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our commitment to build <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;best-in-class&nbsp;bioprocessing</FONT></FONT> technology company with a world-class direct sales and commercial organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to capitalizing on growth opportunities and maximizing the value of our product platform through both organic growth
initiatives (internal innovation and commercial leverage) and targeted acquisitions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in May 1981 under the laws of
the State of Delaware. Our mailing address and executive offices are located at 41 Seyon Street, Waltham, MA 02453 and our telephone number at that address is (781) <FONT STYLE="white-space:nowrap">250-0111.</FONT> We maintain an Internet website at
the following address: www.repligen.com. The information on, or that can be accessed through, our website does not constitute part of this prospectus, and you should not rely on any such information in making the decision whether to purchase our
common stock. Our common stock trades on the Nasdaq Global Select Market under the symbol &#147;RGEN.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_7"></A><A NAME="suprom90736_19"></A>DESCRIPTION OF CAPITAL STOCK
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description of our capital stock is intended as a summary only. This description is based upon, and is qualified by
reference to, our restated certificate of incorporation, as amended, or certificate of incorporation, our second amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> or <FONT STYLE="white-space:nowrap">by-laws,</FONT> and applicable
provisions of the Delaware General Corporation Law. This summary is not intended to be a complete description of our capital stock. You should read our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> for the
provisions that are important to you. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 80,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock,
par value $0.01 per share, all of which shares of preferred stock are undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;29, 2019, 44,073,998 shares of our
common stock were outstanding and held by 352 stockholders of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares of our common stock from time to time. Holders of shares of our common stock are entitled to one vote for each share held
of record on all matters to be voted on by stockholders and do not have cumulative voting rights. Subject to the rights of holders of any future series of undesignated preferred stock which may be designated, each share of the outstanding common
stock is entitled to participate ratably in any distribution of net assets made to the stockholders in the event of our liquidation, dissolution or winding up and is entitled to participate equally in dividends if and when declared by our board of
directors. There are no redemption, sinking fund, conversion or preemptive rights with respect to shares of common stock. All shares of common stock have equal rights and preferences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange Listing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock
is listed on the Nasdaq Global Select Market under the trading symbol &#147;RGEN.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and
registrar&#146;s address is 6201 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue Brooklyn, N.Y. 11219, and its telephone number is (718) <FONT STYLE="white-space:nowrap">921-8200.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares of
preferred stock in one or more series. Our board of directors will determine the rights, preferences and privileges of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, including dividend rights,
conversion rights, preemptive rights, voting rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will
be convertible into our common stock or exchangeable for other securities. Conversion may be mandatory or at the holder&#146;s option and would be at prescribed conversion rates. These rights, preferences and privileges could include dividend
rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock.
The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred
stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of our Certificate of Incorporation and
<FONT STYLE="white-space:nowrap">By-laws</FONT> and Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and our <FONT
STYLE="white-space:nowrap">by-laws</FONT> include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other
unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap">by-laws</FONT> provide that a special meeting of the stockholders may be called by the President, the Chairman, the board of directors, or upon the written request of one or more stockholders holding in the aggregate at
least 30% of the outstanding shares of our stock entitled to vote at such meeting; and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our <FONT
STYLE="white-space:nowrap">by-laws</FONT> limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap">by-laws</FONT> establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders.
These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal
executive offices not less than 60 days nor more than 90 days prior to the first anniversary date of the annual meeting for the preceding year. Our <FONT STYLE="white-space:nowrap">by-laws</FONT> specify the requirements as to form and content of
all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law, must
thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class. Our <FONT STYLE="white-space:nowrap">by-laws</FONT> may be
amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the <FONT STYLE="white-space:nowrap">by-laws;</FONT> and may also be amended by the affirmative vote of the holders of a majority
of the outstanding shares entitled to vote at any regular meeting of stockholders, or at any special meeting of stockholders provided notice of such alteration, amendment, repeal or adoption of
<FONT STYLE="white-space:nowrap">new&nbsp;by-laws&nbsp;must</FONT> have been stated in the notice of such special meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred
Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for 5,000,000 authorized shares of preferred stock. The existence of authorized
but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise
of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder
approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of
directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of
shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly
held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the
assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_8"></A><A NAME="suprom90736_20"></A>DESCRIPTION OF DEBT SECURITIES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer debt securities which may be senior or subordinated. We refer to senior debt securities and subordinated debt securities
collectively as debt securities. Each series of debt securities may have different terms. The following description summarizes the general terms and provisions of the debt securities. We will describe the specific terms of the debt securities and
the extent, if any, to which the general provisions summarized below apply to any series of debt securities in the prospectus supplement relating to the series and any applicable free writing prospectus that we authorize to be delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue senior debt securities from time to time, in one or more series under a senior indenture to be entered into between us and a
senior trustee to be named in a prospectus supplement, which we refer to as the senior trustee. We may issue subordinated debt securities from time to time, in one or more series under a subordinated indenture to be entered into between us and a
subordinated trustee to be named in a prospectus supplement, which we refer to as the subordinated trustee. The forms of senior indenture and subordinated indenture are filed as exhibits to the registration statement of which this prospectus
forms&nbsp;a part. Together, the senior indenture and the subordinated indenture are referred to as the indentures and, together, the senior trustee and the subordinated trustee are referred to as the trustees. This prospectus briefly outlines some
of the provisions of the indentures. The following summary of the material provisions of the indentures is qualified in its entirety by the provisions of the indentures, including definitions of certain terms used in the indentures. Wherever we
refer to particular sections or defined terms of the indentures, those sections or defined terms are incorporated by reference in this prospectus or the applicable prospectus supplement. You should review the indentures that are filed as exhibits to
the registration statement of which this prospectus forms&nbsp;a part for additional information. As used in this prospectus, the term &#147;debt securities&#148; includes the debt securities being offered by this prospectus and all other debt
securities issued by us under the indentures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not limit the amount of debt securities that we may issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow us to issue debt securities in one or more series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not require us to issue all of the debt securities of a series at the same time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow us to reopen a series to issue additional debt securities without the consent of the holders of the debt
securities of such series. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, the senior debt
securities will be unsubordinated obligations and will rank equally with all of our other unsecured and unsubordinated indebtedness. Payments on the subordinated debt securities will be subordinated to the prior payment in full of all of our senior
indebtedness, as described under &#147;&#151;Subordination&#148; and in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides
that we may, but need not, designate more than one trustee under an indenture. Any trustee under an indenture may resign or be removed and a successor trustee may be appointed to act with respect to the series of debt securities administered by the
resigning or removed trustee. If two or more persons are acting as trustee with respect to different series of debt securities, each trustee shall be a trustee of a trust under the applicable indenture separate and apart from the trust administered
by any other trustee. Except as otherwise indicated in this prospectus, any action described in this prospectus to be taken by each trustee may be taken by each trustee with respect to, and only with respect to, the one or more series of debt
securities for which it is trustee under the applicable indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement for each offering will provide the following terms, where
applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities and whether they are senior or subordinated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount of the debt securities being offered, the aggregate principal amount of the debt
securities outstanding as of the most recent practicable date and any limit on their aggregate principal amount, including the aggregate principal amount of debt securities authorized; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the debt securities will be issued, expressed as a percentage of the principal and, if other
than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible into
common stock or other securities of ours or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if convertible, the terms on which such debt securities are convertible, including the initial conversion price
or rate and the conversion period and any applicable limitations on the ownership or transferability of common stock or other securities of ours received on conversion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, on which the principal of the debt securities
will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or
rates is determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, from which interest will accrue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the record dates for interest payment dates, or the method by which such dates will be determined;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the persons to whom interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where the principal of, and any premium or make-whole amount, and interest on, the debt
securities will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the debt securities may be surrendered for registration of transfer or conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the times, prices and other terms and conditions upon which we may redeem the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem, repay or repurchase the debt securities pursuant to any sinking fund or
analogous provision or at the option of holders of the debt securities, and the times and prices at which we must redeem, repay or repurchase the debt securities as a result of such obligation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies in which the debt securities are denominated and payable if other than United States
dollars, which may be a foreign currency or units of two or more foreign currencies or a composite currency or currencies and the terms and conditions relating thereto, and the manner of determining the equivalent of such foreign currency in United
States dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the principal of, and any premium or make-whole amount, or interest on, the debt securities of the series
are to be payable, at our election or at the election of a holder, in a currency or currencies other than that in which the debt securities are denominated or stated to be payable, and other related terms and conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be in registered form, bearer form, or both, and (i)&nbsp;if in registered form,
the person to whom any interest shall be payable, if other than the person in whose name the security is registered at the close of business on the regular record date for such interest, or (ii)&nbsp;if in bearer form, the manner in which, or the
person to whom, any interest on the security shall be payable if otherwise than upon presentation and surrender upon maturity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions applicable to the offer, sale or delivery of securities in bearer form and the terms upon which
securities in bearer form of the series may be exchanged for securities in registered form of the series and vice versa, if permitted by applicable laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any debt securities of the series are to be issuable initially in temporary global form and whether any
debt securities of the series are to be issuable in permanent global form with or without coupons and, if so, whether beneficial owners of interests in any such permanent global security may, or shall be required to, exchange their interests for
other debt securities of the series, and the manner in which interest shall be paid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the depositary for securities in registered form, if such series are to be issuable as a global
security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability, if any, of the defeasance and covenant defeasance provisions described in this prospectus or
in the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances we will pay any additional amounts on the debt securities in respect of any
tax, assessment or governmental charge; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances the debt securities being offered are convertible into common stock or other
securities of ours, as the case may be, including the conversion price or rate and the manner or calculation thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the applicable trustee and the nature of any material relationship with us or any of our affiliates,
and the percentage of debt securities of the class necessary to require the trustee to take action; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such debt securities not inconsistent with the provisions of the applicable indenture.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for less than the entire principal amount thereof to be payable upon
declaration of acceleration of the maturity of the debt securities. We refer to any such debt securities throughout this prospectus as &#147;original issue discount securities.&#148; The applicable prospectus supplement will describe the United
States federal income tax consequences and other relevant considerations applicable to original issue discount securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
described under &#147;&#151;Merger, Consolidation or Sale of Assets&#148; or as may be set forth in any prospectus supplement, the debt securities will not contain any provisions that (i)&nbsp;would limit our ability to incur indebtedness or
(ii)&nbsp;would afford holders of debt securities protection in the event of (a)&nbsp;a highly leveraged or similar transaction involving us, or (b)&nbsp;a change of control or reorganization, restructuring, merger or similar transaction involving
us that may adversely affect the holders of the debt securities. In the future, we may enter into transactions, such as the sale of all or substantially all of our assets or a merger or consolidation, that may have an adverse effect on our ability
to service our indebtedness, including the debt securities, by, among other things, substantially reducing or eliminating our assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
governing instruments do not define the term &#147;substantially all&#148; as it relates to the sale of assets. Additionally, Delaware cases interpreting the term &#147;substantially all&#148; rely upon the facts and circumstances of each particular
case. Consequently, to determine whether a sale of &#147;substantially all&#148; of our assets has occurred, a holder of debt securities must review the financial and other information that we have disclosed to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide you with more information in the applicable prospectus supplement regarding any deletions, modifications, or additions to the
events of default or covenants that are described below, including any addition of a covenant or other provision providing event risk or similar protection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, the principal of, and any premium or make-whole amount, and interest on, any
series of the debt securities will be payable by mailing a check to the address of the person entitled to it as it appears in the applicable register for the debt securities or by wire transfer of funds to that person at an account maintained within
the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All monies that we pay to a paying agent or a trustee for the payment of the principal of, and any premium or
make-whole amount, or interest on, any debt security will be repaid to us if unclaimed at the end of two years after the obligation underlying payment becomes due and payable. After funds have been returned to us, the holder of the debt security may
look only to us for payment, without payment of interest for the period which we hold the funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Denomination, Interest, Registration and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, the debt securities of any series will be issuable in denominations
of $1,000 and integral multiples of $1,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest on the debt securities shall be computed on the basis of a <FONT
STYLE="white-space:nowrap">360-day</FONT> year composed of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
limitations imposed upon debt securities that are evidenced by a computerized entry in the records of a depository company rather than by physical delivery of a note, a holder of debt securities of any series may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange them for any authorized denomination of other debt securities of the same series and of a like aggregate
principal amount and kind upon surrender of such debt securities at the corporate trust office of the applicable trustee or at the office of any transfer agent that we designate for such purpose; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">surrender them for registration of transfer or exchange at the corporate trust office of the applicable trustee
or at the office of any transfer agent that we designate for such purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every debt security surrendered for
registration of transfer or exchange must be accompanied by a written instrument of transfer satisfactory to the applicable trustee or transfer agent. Payment of a service charge will not be required for any registration of transfer or exchange of
any debt securities, but we or the trustee may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. We may at any time designate additional transfer agents for any series of debt
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor any trustee, will be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of or exchange debt securities of any series during a period beginning at the
opening of business 15&nbsp;days before the day that the notice of redemption of any debt securities selected for redemption is mailed and ending at the close of business on the day of such mailing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt security, or portion thereof, so selected for redemption, in whole
or in part, except the unredeemed portion of any debt security being redeemed in part; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of or exchange any debt security that has been surrendered for repayment at the
option of the holder, except the portion, if any, of such debt security not to be so repaid. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger, Consolidation or Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that we may, without the consent of the holders of any outstanding debt securities, (i)&nbsp;consolidate with,
(ii)&nbsp;sell, lease or convey all or substantially all of our assets to, or (iii)&nbsp;merge with or into, any other entity provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either we are the continuing entity, or the successor entity, if other than us, assumes the obligations
(a)&nbsp;to pay the principal of, and any premium or make-whole amount, and interest on, all of the debt securities and (b)&nbsp;to duly perform and observe all of the covenants and conditions contained in the applicable indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the transaction, there is no event of default under the applicable indentures and no event
which, after notice or the lapse of time, or both, would become such an event of default, occurs and continues; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an officers&#146; certificate and legal opinion covering such conditions are delivered to each applicable
trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default, Notice and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, when we refer to &#147;events of default&#148; as defined in the indentures with
respect to any series of debt securities, we mean: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any installment of interest on any debt security of such series continuing for
90&nbsp;days unless such date has been extended or deferred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of, or any premium or make-whole amount on, any debt security of such series
when due and payable unless such date has been extended or deferred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any covenant or warranty in the debt securities or in the indenture by us
continuing for 90&nbsp;days after written notice described below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy, insolvency or reorganization, or court appointment of a receiver, liquidator or trustee of us; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided with respect to a particular series of debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default occurs and is continuing with respect to debt securities of any series outstanding, then the
applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the principal amount of all the debt securities of that series to be due and payable. If the debt securities of
that series are original issue discount securities or indexed securities, then the applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the portion of the principal
amount as may be specified in the terms thereof to be due and payable. However, at any time after such a declaration of acceleration has been made, but before a judgment or decree for payment of the money due has been obtained by the applicable
trustee, the holders of at least a majority in principal amount of outstanding debt securities of such series or of all debt securities then outstanding under the applicable indenture may rescind and annul such declaration and its consequences if:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have deposited with the applicable trustee all required payments of the principal, any premium or make-whole
amount, interest and, to the extent permitted by law, interest on overdue installment of interest, plus applicable fees, expenses, disbursements and advances of the applicable trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all events of default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated
principal, or a specified portion thereof, and any premium or make-whole amount, have been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures require each trustee to give notice to the holders of debt securities within
the later of 90&nbsp;days after an event of default and 30 days after the event of default is actually known to a responsible officer of such trustee, unless such default has been cured or waived. However, the trustee may withhold notice if
specified persons of such trustee consider such withholding to be in the interest of the holders of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures
provide that holders of debt securities of any series may not institute any proceedings, judicial or otherwise, with respect to such indenture or for any remedy under the indenture, unless the trustee fails to act for a period of 90&nbsp;days after
the trustee has received a written request to institute proceedings in respect of an event of default from the holders of 25% or more in principal amount of the outstanding debt securities of such series, as well as an offer of indemnity reasonably
satisfactory to the trustee. However, this provision will not prevent any holder of debt securities from instituting suit for the enforcement of payment of the principal of, and any premium or make-whole amount, and interest on, such debt securities
at the respective due dates thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that, subject to provisions in each indenture relating to its duties in the
case of a default, a trustee has no obligation to exercise any of its rights or powers at the request or direction of any holders of any series of debt securities then outstanding under the indenture, unless the holders have offered to the trustee
reasonable security or indemnity. The holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under an indenture shall have the right to direct the time, method
and place of conducting any proceeding for any remedy available to the applicable trustee, or of exercising any trust or power conferred upon such trustee. However, a trustee may refuse to follow any direction which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is in conflict with any law or the applicable indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may involve the trustee in personal liability; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may be unduly prejudicial to the holders of debt securities of the series not joining the proceeding.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120&nbsp;days after the close of each fiscal year, we will be required to deliver to each trustee a certificate,
signed by one of our several specified officers, stating whether or not that officer has knowledge of any default under the applicable indenture. If the officer has knowledge of any default, the notice must specify the nature and status of the
default. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indentures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that modifications and amendments may be made only with the consent of the affected holders of a majority in principal
amount of all outstanding debt securities issued under that indenture: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our respective trustee may make modifications and
amendments of an indenture without the consent of any holder of debt securities for any of the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence the succession of another person to us as obligor under such indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants for the benefit of the holders of all or any series of debt securities or to surrender
any right or power conferred upon us in such indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add events of default for the benefit of the holders of all or any series of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication, and delivery of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any securityholder in any material respect;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish the form or terms of debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the acceptance of appointment by a successor trustee or facilitate the administration of the
trusts under an indenture by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in an indenture, provided that such action shall not adversely
affect the interests of holders of debt securities of any series issued under such indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that in determining whether the holders of the requisite principal amount of outstanding debt securities of a series
have given any request, demand, authorization, direction, notice, consent or waiver under the indentures or whether a quorum is present at a meeting of holders of debt securities, the principal amount of an original issue discount security that
shall be deemed to be outstanding shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon declaration of acceleration of the maturity thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided
in the applicable prospectus supplement, subordinated debt securities will be subject to the following subordination provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any
distribution to our creditors in a liquidation, dissolution or reorganization, the payment of the principal of and interest on any subordinated debt securities will be subordinated to the extent provided in the applicable indenture in right of
payment to the prior payment in full of all senior debt. However, our obligation to make payments of the principal of and interest on such subordinated debt securities otherwise will not be affected. No payment of principal or interest will be
permitted to be made on subordinated debt securities at any time if a default on senior debt exists that permits the holders of such senior debt to accelerate its maturity and the default is the subject of judicial proceedings or we receive notice
of the default. After all senior debt is paid in full and until the subordinated debt securities are paid in full, holders of subordinated debt securities will be subrogated to the rights of holders of senior debt to the extent that distributions
otherwise payable to holders of subordinated debt securities have been applied to the payment of senior debt. The subordinated indenture will not restrict the amount of senior debt or other indebtedness of ours. As a result of these subordination
provisions, in the event of a distribution of assets upon insolvency, holders of subordinated debt securities may recover less, ratably, than our general creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No restrictions will be included in any indenture relating to subordinated debt securities upon the creation of additional senior debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this prospectus is being delivered in connection with the offering of a series of subordinated debt securities, the accompanying prospectus
supplement or the information incorporated in this prospectus by reference will set forth the approximate amount of senior debt outstanding as of the end of our most recent fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge, Defeasance and Covenant Defeasance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, the indentures allow us to discharge our obligations to holders of any
series of debt securities issued under any indenture when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either (i)&nbsp;all securities of such series have already been delivered to the applicable trustee for
cancellation; or (ii)&nbsp;all securities of such series have not already been delivered to the applicable trustee for cancellation but (a)&nbsp;have become due and payable, (b)&nbsp;will become due and payable within one year, or (c)&nbsp;if
redeemable at our option, are to be redeemed within one year, and we have irrevocably deposited with the applicable trustee, in trust, funds in such currency or currencies, currency unit or units or composite currency or currencies in which such
debt securities are payable, an amount sufficient to pay the entire indebtedness on such debt securities </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
in respect of principal and any premium or make-whole amount, and interest to the date of such deposit if such debt securities have become due and payable or, if they have not, to the stated
maturity or redemption date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have paid or caused to be paid all other sums payable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an officers&#146; certificate and an opinion of counsel stating the conditions to discharging the debt securities
have been satisfied has been delivered to the trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus
supplement, the indentures provide that, upon our irrevocable deposit with the applicable trustee, in trust, of an amount, in such currency or currencies, currency unit or units or composite currency or currencies in which such debt securities are
payable at stated maturity, or government obligations, or both, applicable to such debt securities, which through the scheduled payment of principal and interest in accordance with their terms will provide money in an amount sufficient to pay the
principal of, and any premium or make-whole amount, and interest on, such debt securities, and any mandatory sinking fund or analogous payments thereon, on the scheduled due dates therefor, the issuing company shall be released from its obligations
with respect to such debt securities under the applicable indenture or, if provided in the applicable prospectus supplement, its obligations with respect to any other covenant, and any omission to comply with such obligations shall not constitute an
event of default with respect to such debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, we may not elect to defease and be discharged from the
obligation to pay any additional amounts upon the occurrence of particular events of tax, assessment or governmental charge with respect to payments on such debt securities and the obligations to register the transfer or exchange of such debt
securities, to replace temporary or mutilated, destroyed, lost or stolen debt securities, to maintain an office or agency in respect of such debt securities, or to hold monies for payment in trust. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may further describe the provisions, if any, permitting such defeasance or covenant defeasance, including
any modifications to the provisions described above, with respect to the debt securities of or within a particular series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions, if any, upon which the debt securities are convertible into common stock or other securities of ours will be set
forth in the applicable prospectus supplement. The terms will include whether the debt securities are convertible into shares of common stock or other securities of ours, the conversion price, or manner of calculation thereof, the conversion period,
provisions as to whether conversion will be at the issuing company&#146;s option or the option of the holders, the events requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption of the debt
securities and any restrictions on conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Recourse </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No recourse shall be had under any obligation, covenant or agreement of ours in the senior indenture or any supplemental indenture, or in any
of the debt securities or because of the creation of any indebtedness represented thereby, against any of our incorporators, stockholders, officers or directors, past, present or future, or of any predecessor or successor entity thereof under any
law, statute or constitutional provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise. Each holder, by accepting the debt securities, waives and releases all such liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the
debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_9"></A><A NAME="suprom90736_21"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase debt securities, common stock, or preferred stock. We may offer warrants separately or together with one or
more additional warrants, debt securities, common stock, or preferred stock, or any combination of those securities in the form of units, as described in the applicable prospectus supplement. If we issue warrants as part of a unit, the accompanying
prospectus supplement will specify whether those warrants may be separated from the other securities in the unit prior to the expiration date of the warrants. The applicable prospectus supplement will also describe the following terms of any
warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific designation and aggregate number of, and the offering price at which we will issue, the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will begin and the date on which that right will expire or,
if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants are to be sold separately or with other securities as parts of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants will be issued in definitive or global form or in any combination of these forms, although,
in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable material U.S. federal income tax consequences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents,
transfer agents, registrars or other agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any
securities exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of any equity securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon
exercise of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the debt securities, common stock, or preferred stock with which the
warrants are issued and, the number of warrants issued with each security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which any warrants issued as part of a unit and the related debt
securities, common stock, or preferred stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon exercise of a warrant and the price at
which those shares may be purchased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the antidilution provisions of, and other provisions for changes to or adjustment in the exercise price of, the
warrants, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or call provisions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange or
exercise of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific warrant agreements will contain additional important terms and provisions and will
be incorporated by reference as an exhibit to the registration statement of which this prospectus forms&nbsp;a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_10"></A><A NAME="suprom90736_22"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information that we include in any applicable prospectus supplements and in any
related free writing prospectuses, summarizes the material terms and provisions of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that we may offer under this prospectus,
we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that
we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and
provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable
prospectus supplements related to the particular series of units that we may offer under this prospectus, as well as any related free writing prospectuses and the complete unit agreement and any supplemental agreements that contain the terms of the
units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units
comprised of shares of common stock, preferred stock, debt securities, warrants and units in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a
unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any
time before a specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of units, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation and terms of the units, including whether and under what circumstances the securities comprising the
units may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement that differ from those described below; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#147;Description of
Capital Stock,&#148; &#147;Description of Debt Securities&#148; and &#147;Description of Warrants,&#148; will apply to each unit and to the common stock, preferred stock, debt securities and warrants included in each unit, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units in
such amounts and in such numerous distinct series as we determine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency
or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit,
including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate
legal action its rights as holder under any security included in the unit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the unit agent and any of its agents, may treat the registered holder of any unit certificate as an absolute owner of the units evidenced
by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_11"></A><A NAME="suprom90736_23"></A>FORMS OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt security, warrant and unit will be represented either by a certificate issued in definitive form to a particular investor or by one
or more global securities representing the entire issuance of securities. Unless otherwise provided in the applicable prospectus supplement, certificated securities in definitive form and global securities will be issued in registered form.
Definitive securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the
securities to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the debt securities, warrants or units represented by these global securities. The depositary
maintains a computerized system that will reflect each investor&#146;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registered Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the registered debt securities, warrants and units in the form of one or more fully registered global securities that will be
deposited with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global securities will be issued in a denomination or
aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive registered form, a
registered global security may not be transferred except as a whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the depositary or those nominees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered
global security will be described in the prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a registered global security will be limited to persons, called participants, that have accounts with the
depositary or persons that may hold interests through participants. Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#146; accounts with the
respective principal or face amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of
beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of
participants, with respect to interests of persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability
to own, transfer or pledge beneficial interests in registered global securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the depositary, or its nominee, is the
registered owner of a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner or holder of the securities represented by the registered global security for all purposes under the applicable
indenture, warrant agreement or unit agreement. Except as described below, owners of beneficial interests in a registered global security will not be entitled to have the securities represented by the registered global security registered in their
names, will not receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders of the securities under the applicable indenture, warrant agreement or unit agreement.
Accordingly, each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant, on the procedures of the participant
through which the person owns its interest, to exercise any rights of a holder under the applicable indenture, warrant agreement or unit agreement. We understand that under existing industry practices, if we request any action of holders or if an
owner of a beneficial interest in a registered global security </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
desires to give or take any action that a holder is entitled to give or take under the applicable indenture, warrant agreement or unit agreement, the depositary for the registered global security
would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the
instructions of beneficial owners holding through them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal, premium, if any, and interest payments on debt securities, and any
payments to holders with respect to warrants, or units, represented by a registered global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of
the registered global security. None of us, the trustees, the warrant agents, the unit agents or any other agent of ours, agent of the trustees or agent of the warrant agents or unit agents will have any responsibility or liability for any aspect of
the records relating to payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment to holders of
principal, premium, interest or other distribution of underlying securities or other property on that registered global security, will immediately credit participants&#146; accounts in amounts proportionate to their respective beneficial interests
in that registered global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests in a registered global security held through participants will be governed by standing
customer instructions and customary practices, as is now the case with the securities held for the accounts of customers or registered in &#147;street name,&#148; and will be the responsibility of those participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary for any of the securities represented by a registered global security is at any time unwilling or unable to continue as
depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90&nbsp;days, we will issue securities in definitive form
in exchange for the registered global security that had been held by the depositary. Any securities issued in definitive form in exchange for a registered global security will be registered in the name or names that the depositary gives to the
relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs. It is expected that the depositary&#146;s instructions will be based upon directions received by the depositary from participants with respect to ownership of
beneficial interests in the registered global security that had been held by the depositary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_12"></A><A NAME="suprom90736_24"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, the
net proceeds received by us from our sale of the securities described in this prospectus will be added to our general funds and will be used for our general corporate purposes. From time to time, we may engage in additional public or private
financings of a character and amount which we may deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_13"></A><A NAME="suprom90736_25"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities through any one or more of the following methods from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters, brokers or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to one or more other purchasers in negotiated sales or competitively bid transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a block trade in which the broker or dealer engaged to handle the block trade will attempt to sell the
securities as agent, but may position and resell a portion of the block as principal to facilitate the transaction; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of the above methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. We will, in the prospectus
supplement relating to such offering, name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that we must pay. Any such agent will be acting on a best efforts basis for the period of its
appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price, or prices, which may be changed from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the agent or any underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering or purchase price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to the agent or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other items constituting underwriting compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any exchanges on which the securities will be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any underwriters or agents are utilized in the sale of the securities in respect of which this prospectus is delivered, we will enter into
an underwriting agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with
them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect of which the prospectus is delivered, we will sell such securities
to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer securities in a subscription rights offering to our existing security holders, we may enter into a standby underwriting agreement
with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting arrangement, we may retain a
dealer-manager to manage a subscription rights offering for us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, underwriters, dealers and other persons may be entitled under agreements which they
may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary course of business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit
offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and the
aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and
savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any
conditions except that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which that institution is subject; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are also being sold to underwriters acting as principals for their own account, the
underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain agents, underwriters and dealers, and their associates and affiliates may be customers of, have borrowing
relationships with, engage in other transactions with, or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in
any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases
previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels.
Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under <FONT
STYLE="white-space:nowrap">Rule&nbsp;15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus
supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the
second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than two scheduled business days after the trade date for your
securities, to make alternative settlement arrangements to prevent a failed settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities
and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In compliance with the guidelines of the Financial Industry Regulatory Authority, or FINRA, the aggregate maximum discount, commission or
agency fees or other items constituting underwriting compensation to be received by any FINRA member or independent broker-dealer will not exceed 8% of the proceeds from any offering pursuant to this prospectus and any applicable prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_14"></A><A NAME="suprom90736_26"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon by Goodwin Procter LLP, Boston, Massachusetts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc668819_15"></A><A NAME="suprom90736_27"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Repligen Corporation appearing in Repligen Corporation&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, and the effectiveness of Repligen Corporation&#146;s internal control over financial reporting as of December&nbsp;31, 2018 have been audited by Ernst&nbsp;&amp; Young
LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such
reports given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>1,500,000 shares </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90736g68g84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Repligen Corporation </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Stifel</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Co-Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Craig-Hallum&nbsp;Capital&nbsp;Group</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Stephens&nbsp;Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g90736g54m58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90736g54m58.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( "\!%P,!$0 "$0$#$0'_Q  >   !! ,! 0$
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MW$Z0/J7=&J=G$B-Y>+%U_L*IW L1I.<)RZ6+ 2T@0*WC*DXRI]MM.,J3]_\
M"QXR&LJ %SH -V;D3H*EWV)U7<-U:KJVS)XB%$@]?6"^U>'NDN59"T@5X>,K
M)\FQ,'/SART!Q+0P;BY E26!4NN9PGI#V 9.@,Z '>R]NZKTS!B6;;NR*-K"
MN2$JS! SU_M,)48@R:($-/8B1I&=-!$?DG@8V0,:";=40X,"6^EO+8[JD(G
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M[@@K;8H3\FZ$,VAD="<<ZE#:!7][C7UXG%S\N^'WZT .MT_15W] 6X>N8,Z
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M:G7@:-==?CA[?686RL /OH2V^\$U-!&MBNO-H0AUQA+:W$(2E><I3C&$M8<
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M*,\MR0JEAA2"ZQ."(:>*!@)@QR.P#,"QY VVUVCX:?\ S?S,QKMQ1UG^P5[
MV%JQS1.K]A[=GX*FSINT.6EAJ6M=K:X/W;K^R2)VZ[JHVKVF%K&71QI^NX*C
M8NLW4"<"9@,F2S@/S2-,+"<JF7$X5TX:^71OTUY$<0I>M65*=VO(,I^I;1NS
M9UC/S5Z'1Y=6IN-9PUNDEOSNPM.R>7;I,S .KY:);'RDX93.(Y<E\^BHPYY@
M4HT&=CL$1KT3A;J7;1V6?Z96IS9VZ[N-NIY7*F3%UDZ17LUZE6UDKF1OHMV
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M !Y9?A;S[F/#OG0&]#G]>SNTE4;7+2&N35=Y5[7L&R9>+CR8,EC3^=ZWJ0F
M[W8GV8^/OT+*ZQ*"@:U6F"[45!39E;*1'0N:^Z;%G,2_I:276%C:^MK2M8>5
MEK7B\LWWM(O:U,66CGWFN'A/S,/PH@KD]20%R3?^.TIL..*=T5'*?63A8SM)
MU4>9KN4,EU,#%2%CS,^HTV"XXR=X>.+/*/J\[[V@M_"W5O$^*GF^0B!J7L6A
MZSW3H39PL4<NZU"D;'&DZ]>)BS,3LU*S]<IF[GGSY2M4>1KJ[%8QP+RF+%!?
M$1(7JP>PEG%,+&&9:=.5;;=K7:W1$PFGA\V^KQNT^I[R ^X@B^4&OY60FIV?
MUMHS1\$); +"+&V#8VKP]B[<GY.::/0?'J@-ARNL7I.H34D\1#+)N\2388PF
M/C)"+='6L]&ZK:)Q3;I..5F+RTLI1/6(VNE/*>HG=D[)XH6C0]>L&@%:SKNL
MX7?&NL["*(TK8,TY"E1,]E3EOUZ,'1YF^9]'(J24AENOD.>W<6>][92,6*E4
MU5,\+B\N^SO&6)42K*;VY;+.A\.Y[_QM%U%HVXKO&H26H\#;C>N*83QMMZ]$
M[-EW)B)1/AMZN?*D)?7EI EP0(ZO7LRS(<AR+!:9)M$M%39\<V7%-2AZ2^+Y
MDNNJ<W4;;!M1,XY6GI]Y_ ^79STS)?<LG.QSD(:_N6KG3D.W(M%XB\/ZEV6L
MR+<.:6AF4;!.>:&R\SA;92F4$MHRCP4G'^73[HWU]MV&ET^+O%$LVA8U11LI
MK[9_)&]6EA),JEXJDW>,1NA,Y!L-O$J?*J=ZA\#6D$,9+K,!:8:TK*SA%IBA
M@=.'Q1HEX33Z.W2-KY4J$[SOHX_OVQ-\\Y.H!;=9 M]GI-7+L7'^1A: =:M4
MSVS)U-U(MLMAA>N92$L4$WK*Y)PL+(5YD_<A!/\ LGE-JP MM5H4JW^5[VA*
M\IYZ==P\K29TOIC;J$?9ZK:Y#[;FY\&5C(8.M<.;#MJNL6-H^2QKN(LT[+;J
MKS<R,4&F8RFK-RPLW[-P9RXQ+$C%@)(?E61G(K1UJ2;W:23CW#%2MR43S2S^
M0?-$Z\V30]]S?&B(KJM 3Y'&JKQ-<;A7ZAK^<V>!M]Q>S'6**9&QY,'"R=.F
M*!!VYY5:"'M:A"%, 2;@I)<C;J)GBBI\THM??+R%#G:RY3C'@$FW\?9F$'U3
M4WH'4LK%W7E+)VQG5!D 6=I"FPHG%7;,2BN@5X[&%&!D6*O(NR_8PL3'CW*8
M5*"UX=T0F0,B?U?ZQ.']2ZZ6SBTZ",3OC*P_?N6+5SVL]>4W0<KRH2+*Z:A8
M;>E+L$)9(,V\4RH;Z1LP)8U9^AS&;>=8:Y386+O5&U18' I]J!J\(THLF*-G
M6%JL-MJG-GLVDKM];-K<DI)<3W41SOB5;3W&UDIRB46D<?K;R0'69QB)QOA$
M!#VL<B_1,01<-DQL]Q@1<:F)BQ'V1$/I-J;@(3#L=86Z=(/L,RV$'(&F0EVZ
MDOJMBV%\T=[O?38NTJWY?R^5M>>YX;,O6BX[?M1F):;TY!:YL/'KCX1JD"_\
M?+;L]DJ(;O6['G&-?"0$W6DZK<;ACJJR0Y,PA2"T+K[;8#.*N6&LDW3%YXJI
MO&E.=[SKON24GF%"T>+^ O(6WZJB.;$I U&8JNPMCV*T6$F_QEAUS*!;/U'&
M16L"$/FU3<9#8,5.4!QZ&@HE.M4-2IHQ=R?F0)4<2)-CVY=T3=)8AV=[RM[Y
MY8FY;<7/I?&_31]L0!+5=EUS(ZVW93-&357V-78"NZR=D=LQNOY36.RI&97L
M)I@2#VV;+HCE;2MC\:T?,N;)#C(CW3KLDQ*BNR4@HLJO*=5LJ,I*-,PIT"V6
MC4O&JSNX3EBRWM$WFIXY<;#KI!YL!<-K5'75TKZI=#38(;VL]#MT.]UQH@MM
MD.0BK7+2E9L\>/D<F=@+(/+.Y?<ID6&<ICY4]FU;F[?=;-<Q5K&OROOA]I\^
M0,>0^Z:II:1VJY+5C5=ZY; [)L\O6JUMG74S>B[=JRR69A&O!Z)L8&<C(35T
M-5M3DO*EZ\>8P[,3L%.-_)VCK B6FK2F\-JF%+3B-Y5V_FQ[C+A3,-NZE:8]
#$?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g90736g68g84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90736g68g84.jpg
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M4GB1US$U4597=9:TT3)"86)Q>96BTO_$ !T!  $% 0$! 0            <
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MJ'_&^E]0W&7X+9[YKN?1:7U;<'_A-@_G*I]+I>]0[^TAO^,EYK1^VM>[;B(
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MA7OQGQZDIN*>)K"&*QQ%G9XR-C'-E\A*A'H*/892/5MJ.BX:X<@?O(,!A(9
M=P\6*HQN#Z0R0!@=^O0^/7QTX]EEH=IIAAIMAAEM#3++*$MM---IPAMMIM&$
MH;;0C&$H0C&$I3C"4XQC&,=09))))))))).Y)/4DD]22>I)\=30
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;;?T^(V]6PVZ>>O)(4;J!X['IUW]_?^WW]?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
